Form 4: Alnylam Executive Bryan Supran Receives Equity Grant

Alnylam Pharmaceuticals' EVP, CLO, and Secretary, Bryan Supran, was granted 1,539 restricted stock units and options for 3,381 shares.

Summary

• Bryan Supran, EVP, CLO, and Secretary of Alnylam Pharmaceuticals, Inc., received an equity grant on March 2, 2026.
• The grant includes 1,539 restricted stock units (RSUs) and stock options for 3,381 shares of common stock.
• The RSUs represent a contingent right to receive one share of common stock each and will vest over a three-year period, with one-third vesting on each of the first, second, and third anniversaries of the grant date.
• The stock options have an exercise price of $325.07 and will vest as to 25% of the shares on the first anniversary of the grant date, with the remaining shares vesting in equal installments at the end of each successive three-month period until the fourth anniversary of the grant date.
• Both grants are subject to Mr. Supran's continuous service with the Issuer as of each vesting date.
• Following these transactions, Mr. Supran beneficially owns 14,565 shares of common stock directly and 3,381 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting standard executive compensation practices and aligning management incentives with long-term company performance.

Positives

• The equity grants align the interests of EVP, CLO, and Secretary Bryan Supran with those of shareholders, incentivizing long-term performance.
• The grants represent a commitment to retaining key executive talent within Alnylam Pharmaceuticals.

Risks

• The vesting of both RSUs and stock options is contingent upon Bryan Supran's continuous service with Alnylam Pharmaceuticals, Inc., meaning unvested portions would be forfeited upon departure.

Future Outlook

No forward-looking statements or guidance regarding company performance are provided in this Form 4.

Industry Context

StockSavvy.ai notes that equity compensation, such as restricted stock units and stock options, is a standard practice across the biotechnology and pharmaceutical industries to attract, retain, and incentivize executive talent, aligning their long-term interests with shareholder value creation.

Comparison to Industry Standards

• Equity grants with multi-year vesting schedules are a common compensation structure in the biotech sector, comparable to practices at companies like Moderna or BioNTech, designed to foster long-term commitment and performance.
• The specific amounts and vesting schedules are typical for an executive at this level within a publicly traded pharmaceutical company.

Related Party Transactions

• This filing reports an equity grant to an executive, which is a standard compensation arrangement and not typically classified as an unusual related party transaction.

Stakeholder Impact

• Shareholders: Potentially positive due to increased alignment of executive incentives with long-term shareholder value.
• Employees: No direct impact on general employees, but reflects standard executive compensation practices for executives.

Next Steps

• Continued service by Bryan Supran to ensure vesting of RSUs and stock options.
• Vesting of 1,539 RSUs over three years, with one-third vesting annually starting March 2, 2027.
• Vesting of 3,381 stock options over four years, with 25% vesting on March 2, 2027, and remaining portions vesting quarterly thereafter.

Key Dates

Keywords

Alnylam Pharmaceuticals, ALNY, Form 4, insider transaction, equity grant, restricted stock units, RSU, stock options, executive compensation, Bryan Supran